



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/594,851

05/04/2007

Tania Katelic

4964NP-2

2057

22442

7590

04/13/2010

SHERIDAN ROSS PC  
1560 BROADWAY  
SUITE 1200  
DENVER, CO 80202

EXAMINER

HIBBERT, CATHERINE S

ART UNIT

PAPER NUMBER

1636

MAIL DATE

DELIVERY MODE

04/13/2010

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Sequence Compliance Attachment

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, the specification on page 41, bottom paragraph, page 50, second paragraph, and Figures 1, 2, 9, 10, 11, 12, 13, 14, 15 and 16 contain sequences that are not identified by sequence identifier numbers. If the sequences can be found in the sequence listing it would be remedial to insert the appropriate SEQ ID NO:s next to the sequences noted in the specification. In addition, regarding the figures, if the sequences can be found in the sequence listing it would be remedial to insert the appropriate SEQ ID NO:s either in the drawings or in the Brief Description of the Drawings section of the disclosure. If not, a substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification, CRF and letter stating that the contents of the sequence listing and the CRF are the same and contain no new matter is required.